What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Richard Pratley, MD

Richard Pratley, MD

Senior Investigator Translational Research Institute for Metabolism and Diabetes Medical Director, Florida Hospital Diabetes Institute (FHDI) Professor, Sanford-Burnham Medical Research Institute at Lake Nona Orlando, Florida